2022年9月7日

2022年9月07日东部时间上午07:27教堂山,北卡罗来纳州——(业务线)——Areteia疗法,Inc . (“Areteia”)今天宣布,其董事会已经任命伊恩解读为董事会主席。读先生被任命为Areteia首任主席是由Knopp生物科学公司的发射和人口卫生合作伙伴和公司的成功完成首轮融资3.5亿美元由贝恩资本(Bain Capital)生命科学与生物技术的访问,参与全球之声,拱Venture Partners,土星伙伴,赛诺菲,特立独行的资本和人口健康伙伴。“我很兴奋,伊恩已经被任命为董事长,”Jorge Bartolome说,首席执行官Areteia。”他是一个非常受人尊敬的执行的深度体验,证明领导和专家判断将宝贵的我和董事会关注实现公司的战略和推进三期项目dexpramipexole,第一个可能的口服药物嗜酸性哮喘。“评论他的任命,读先生说,“我很荣幸被选为主席Areteia期待与豪尔赫和团队。这是一个引人注目的机会来解决高严重哮喘患者的未满足的需求为市场带来新的口服药物潜在的治疗嗜酸性早些时候哮喘治疗范式,提供病人和卫生系统替代注射生物制剂。“先生读给他带来一个杰出的42年记录作为最重要的领导人之一,交易撮合者,并在全球生物制药产业价值的创造者。他是辉瑞公司的董事长兼首席执行官,公司从2010年12月到2019年1月,执行主席,直到2019年12月。任职期间,他见证了30多个新药审批,880亿美元的收购和剥离交易,250%的股东总回报代表超过2420亿美元的价值创造。读先生负责一段industry-shaping创新关于辉瑞和其投资组合的结构,包括小说赚钱和收购与许多主要的许可协议。读先生目前担任人口健康伙伴的合作伙伴。 About Areteia Therapeutics Areteia Therapeutics, Inc. (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase III clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development, including Phase III clinical trials of dexpramipexole, in partnership with Population Health Partners’ development unit, Validae Health. About Dexpramipexole Dexpramipexole is an oral small molecule in Phase III development for eosinophilic asthma. Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (daily dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation. About Eosinophilic Asthma Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts in a way similar to injectable anti-IL-5 biologic therapies. The asthma biologic market is experiencing growth of 10% per year and is valued at around $8 billion, with IL-5 biologic therapies representing approximately $3 billion of that figure. If approved as a first-to-market oral, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially be used earlier in the asthma treatment paradigm to prevent progression of disease. Contacts